National Health Information Survey 2022 shows that 41.5% of US adults used the Internet to communicate with a doctor’s office; highest in metropolitan areas and decreasing in urban areas https://t.co/utU2YT7mt5 https://t.co/Y4U8ohy71s

BMJ State of the Art (full read) review of ADVANCES in LUPUS THERAPY (Morand EF, et al). - Recent SLE RCTs - Pathogenesis, genetics, epigenetics - Phenotypes - Emerging treatments - Guidelines on Rx https://t.co/OVJRVA8hoz https://t.co/6Srmo5vNjF

Analysis of German RABBIT registry did not show more MACE events in pts w/ JAK inhibitors compared to other DMARDs. 154 MACE w/ 14203 Rx episodes (21218 Pt-Yrs). IRs were 0.68 JAKi, 0.62 TNFi, 0.76 bdMARDs and 0.95 csDMARDs; higher in CV risk pts https://t.co/2UZh4zQFEM https://t.co/VRX2Z8YBrC

FDA has approved another ustekinumab biosimilar (Wezlana) as being interchangeable for use in adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. https://t.co/zbQKjmKgZh https://t.co/UuTDRgCBIV

FDA has approved secukinumab (Cosentyx) for use in adults w/ moderate to severe hidradenitis suppurativa. Recommended dose is 300 mg SC @ wk 0, 1, 2, 3 and 4 and then every 4 weeks thereafter. https://t.co/Pi6RbDbroG https://t.co/AWhbVj2QGa

FDA has approved Abatacept to Treat Juvenile Psoriatic Arthritis (JPsA) in patients aged 2 to 17 years. (JPsA) in patients aged 2 to 17 years. This expands the current indications for ABA use in RA, poly JIA, PsA, and GVHD. https://t.co/eAc8Dsyc3b https://t.co/uHJqhEvuPG

RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today! https://t.co/1SjBiM7Daj https://t.co/w2cFcj85r5

Choosing steroid sparing therapies in #PMR We have no evidence-based alternative treatment to glucocorticoids in PMR. Few disease-modifying anti-rheumatic drugs, such as methotrexate and leflunomide, are used in daily clinical practice in PMR. https://t.co/zvfAwc7t1z https://t.co/pAJFHF6hOn

Blinkers and the Unseen Information Gap in #PMR https://t.co/uZ9qCPmRw9 https://t.co/lrXRdVGNk2

#PMR Mythbusters: PMR Gets 100% Better Within 72 hours https://t.co/lezwD0J8pL https://t.co/QluGHHnH3X

Why should rheumatologists discuss exercise in #PMR? https://t.co/DBnXetbu2K https://t.co/hfjugw661u

Metanalysis of 26 studies (2252) pts w/ HBsAg-/HBcAb+ RA treated with b/tsDMARDs, shows the pooled HBV reactivation rate was 2.0% HBV reactivation higher w/ RTX (9%), ABA (6%), JAKi (1%); none w/ IL-6i or TNF-i More reactivation if pt is HBsAb- (OR=4.56) https://t.co/fSqvkEGbw3 https://t.co/WGCoZ4nQ3d